Overview
- UPS disclosed Monday that it will invest $48 million to outfit 27 temperature-controlled cross-dock sites across the Americas, Europe and Asia to speed transfers between air and ground and limit time in storage.
- The sites are designed as short-term transfer hubs with continuous temperature monitoring to reduce handoffs and the risk of temperature excursions that can spoil vaccines and biologics.
- The investment follows UPS’s recent healthcare dealmaking and growth in the business, including the $1.6 billion Andlauer purchase and the company’s first $3 billion healthcare-revenue quarter in Q1 2026.
- Demand for cold-chain services is being driven by surging use of refrigerated biologics such as GLP-1 weight-loss and diabetes drugs, and analysts forecast the temperature-sensitive biologics market to expand at about an 8.3% CAGR to roughly $39.1 billion by 2033.
- Beyond protecting product value and patient safety, the buildout aims to reduce vaccine and drug waste tied to cold-chain failures and to position UPS competitively as carriers like FedEx also expand healthcare logistics capacity.